Point-of-Care Adipose-Derived Stromal Vascular Fraction Cell Isolation and Expanded Polytetrafluoroethylene Graft Sodding

2017 ◽  
Vol 23 (8) ◽  
pp. 497-504 ◽  
Author(s):  
Stuart K. Williams ◽  
Marvin E. Morris ◽  
Paul E. Kosnik ◽  
Kevin D. Lye ◽  
Gary D. Gentzkow ◽  
...  
Keyword(s):  
Point Of Care ◽  
Stromal Vascular Fraction ◽  
Cell Isolation ◽  
Expanded Polytetrafluoroethylene ◽  
Stromal Vascular Fraction Cell ◽  
Expanded Polytetrafluoroethylene Graft

Adipose Stromal Vascular Fraction Cells Isolated Using an Automated Point of Care System Improve the Patency of Expanded Polytetrafluoroethylene Vascular Grafts

2013 ◽  
Vol 19 (11-12) ◽  
pp. 1295-1302 ◽  
Author(s):  
Stuart K. Williams ◽  
Paul E. Kosnik ◽  
Leigh B. Kleinert ◽  
Erik M. Vossman ◽  
Kevin D. Lye ◽  
...  
Keyword(s):  
Point Of Care ◽  
Vascular Grafts ◽  
Stromal Vascular Fraction ◽  
Expanded Polytetrafluoroethylene ◽  
Point Of Care System ◽  
Care System

scholarly journals Stromal Vascular Fraction for Osteoarthritis of the Knee Regenerative Engineering

2021 ◽  
Author(s):  
Chinedu C. Ude ◽  
Shiv Shah ◽  
Kenneth S. Ogueri ◽  
Lakshmi S. Nair ◽  
Cato T. Laurencin
Keyword(s):  
Quality Of Life ◽  
Clinical Evidence ◽  
Point Of Care ◽  
Stromal Vascular Fraction ◽  
Clinic Visit ◽  
Osteoarthritis Of The Knee ◽  
Clinical Patient ◽  
Inflammatory Proteins ◽  
Anti Inflammatory

Abstract Purpose The knee joint is prone to osteoarthritis (OA) due to its anatomical position, and several reports have implicated the imbalance between catabolic and anabolic processes within the joint as the main culprit, thus leading to investigations towards attenuation of these inflammatory signals for OA treatment. In this review, we have explored clinical evidence supporting the use of stromal vascular fraction (SVF), known for its anti-inflammatory characteristics for the treatment of OA. Methods Searches were made on PubMed, PMC, and Google Scholar with the keywords “adipose fraction knee regeneration, and stromal vascular fraction knee regeneration, and limiting searches within 2017–2020. Results Frequently found interventions include cultured adipose-derived stem cells (ADSCs), SVF, and the micronized/microfragmented adipose tissue-stromal vascular fraction (MAT-SVF). Clinical data reported that joints treated with SVF provided a better quality of life to patients. Currently, MAT-SVF obtained and administered at the point of care is approved by the Food and Drug Administration (FDA), but more studies including manufacturing validation, safety, and proof of pharmacological activity are needed for SVF. The mechanism of action of MAT-SVF is also not fully understood. However, the current hypothesis indicates a direct adherence and integration with the degenerative host tissue, and/or trophic effects resulting from the secretome of constituent cells. Conclusion Our review of the literature on stromal vascular fraction and related therapy use has found evidence of efficacy in results. More research and clinical patient follow-up are needed to determine the proper place of these therapies in the treatment of osteoarthritis of the knee. Lay Summary Reports have implicated the increased inflammatory proteins within the joints as the main cause of osteoarthritis (OA). This has attracted interest towards addressing these inflammatory proteins as a way of treatment for OA. The concentrated cell-packed portion of the adipose product stromal vascular fraction (SVF) from liposuction or other methods possesses anti-inflammatory effects and has been acclaimed to heal OA. Thus, we searched for clinical evidence supporting their use, for OA treatment through examining the literature. Data from various hospitals support that joints treated with SVF provided a better quality of life to patients. Currently, there is at least one version of these products that are obtained and given back to patients during a single clinic visit, approved by the FDA.

Clinical Safety of Stromal Vascular Fraction Separation at the Point of Care

2015 ◽  
Vol 75 (6) ◽  
pp. 666-671 ◽  
Author(s):  
Joel A. Aronowitz ◽  
Ryan A. Lockhart ◽  
Cloe S. Hakakian ◽  
Kevin C. Hicok
Keyword(s):  
Point Of Care ◽  
Stromal Vascular Fraction ◽  
Clinical Safety

scholarly journals Stromal vascular fraction cell therapy for osteoarthritis in elderly: Multicenter case-control study

2019 ◽  
Vol 10 (1) ◽  
pp. 76-80 ◽  
Author(s):  
Jaroslav Michalek ◽  
Alena Vrablikova ◽  
Adas Darinskas ◽  
Ladislav Lukac ◽  
Jaroslav Prucha ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Case Control Study ◽  
Stromal Vascular Fraction ◽  
Case Control ◽  
Stromal Vascular Fraction Cell ◽  
Control Study

scholarly journals Expanded Polytetrafluoroethylene Graft Fistula for Chronic Hemodialysis

1979 ◽  
Vol 189 (1) ◽  
pp. 101-105 ◽  
Author(s):  
VIVIAN A. TELLIS ◽  
WILLIAM I. KOHLBERG ◽  
DINESH J. BHAT ◽  
BARRY DRISCOLL ◽  
FRANK J. VEITH
Keyword(s):  
Chronic Hemodialysis ◽  
Expanded Polytetrafluoroethylene ◽  
Expanded Polytetrafluoroethylene Graft

P3651Outcomes of right ventricular outflow tract reconstruction in children: comparison between bovine jugular vein graft and expanded polytetrafluoroethylene graft

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
K Hirai ◽  
K Baba ◽  
T Goto ◽  
D Ousaka ◽  
H Oh ◽  
...  
Keyword(s):  
Right Ventricular ◽  
Vein Graft ◽  
Jugular Vein ◽  
Pulmonary Stenosis ◽  
Right Ventricular Outflow Tract ◽  
Ventricular Outflow Tract ◽  
Aneurysmal Dilatation ◽  
Expanded Polytetrafluoroethylene ◽  
Expanded Polytetrafluoroethylene Graft ◽  
Bovine Jugular Vein

Abstract Background Various types of conduits are available for right ventricular outflow tract reconstruction (RVOTR). The bovine jugular vein graft (BJVG) and expanded polytetrafluoroethylene graft (ePTFEG) have been descrived as an alternative to the homograft for RVOTR. Purpose- This study summarized the results to evaluate the single-center operation of RVOTR using BJVG and ePTFEG. Methods The valve functions of 27 patients under 20 years old who underwent primary RVOTR with BJVG and 26 patients with ePTFEG at our university hospital between 2013 and 2018 were retrospectively investigated. The valve conditions were assessed using echocardiography and cardiac catheterization. Results The median age at the time of operation was 1.8 years old (range, 6 days to 7.8 years old) with BJVG and 2.2 years old (range, 8 months to 9.1 years old) with ePTFEG. The median follow-up time was 3.4 years (range, 2 months to 5.2 years) with BJVG and 2.1 years (range, 1 month to 5.1 years) with ePTFEG. The peak RVOT gradient of BJVG was lower than ePTFEG (10.6±7.7 mmHg versus 18.1±16.2 mmHg, P=0.035). There were no differences in branch pulmonary stenosis defined as peak gradient up to 36mmHg (40.7% versus 50.0%, P=0.50) and pulmonary regurgitation graded worse than moderate (18.5% versus 11.5%, P=0.48) with BJVG and ePTFEG, respectively. Aneurysmal dilatation of the conduit was seen 22.2% with BJVG but none of patients with ePTFEG (P=0.01). All of patients with aneurysmal dilated BJVG had branch pulmonary stenosis. There were no differences in catheter intervention for branch pulmonary stenosis (22.2% versus 30.8%, P=0.48) and conduit replacement (11.1% versus 7.7%, log rank P=0.67) with BJVG and ePTFEG, respectively. There were no deaths during the fllow-up period in both groups. Conclusions The outcomes of RVOTR with BJVG and ePTFEG were clinically satisfactory. Aneurysmal dilatation was seen with BJVG and branch pulmonary stenosis was the risk factor for aneurysmal dilatation.

Age influence on stromal vascular fraction cell yield obtained from human lipoaspirates

Cytotherapy ◽  
2014 ◽  
Vol 16 (8) ◽  
pp. 1092-1097 ◽  
Author(s):  
Severiano Dos-Anjos Vilaboa ◽  
María Navarro-Palou ◽  
Ramón Llull
Keyword(s):  
Stromal Vascular Fraction ◽  
Cell Yield ◽  
Stromal Vascular Fraction Cell
Sign in / Sign up

Export Citation Format

Share Document